ACI and Ethos Form New Clinical Trial Network
March 18, 2017New Opportunity for Rapid Approval of Innovative Therapies for the Animal Health Market
WOBURN, Mass. (March 8, 2017) — Animal Clinical Investigation (ACI) and Ethos Veterinary Health (Ethos) have formed a strategic alliance offering a new mechanism to deliver market approval of pharmaceuticals and therapeutics in Animal Health. This relationship offers a unique opportunity for collaboration with organizations in the pharmaceutical industry, diagnostic developers and medical device companies.
The two companies are establishing a multi-specialty clinical trial network comprised of a geographically diverse, nationwide collection of Ethos veterinary hospitals. They are selected based on their interest and experience in clinical research, and their depth and strength in the veterinary specialties of internal medicine, dermatology, oncology, emergency and critical care medicine, diagnostic imaging and surgery.
“This is an exciting partnership for Ethos. It will ensure that we are on the forefront of medical discoveries through the participation of our motivated doctors trained in the rigor of conducting clinical trials by ACI, a leading group in veterinary medicine that oversees trial delivery.”
Keith Richter, DVM, MSEL, DACVIM
Chief Medical Officer
ACI, focused on complex medical problems in animals and the design and execution of clinical trials, has been a leader in bringing clinical trials into the private practice setting. Adding the Ethos multi-specialty trial network to ACI’s previously assembled group expands its reach beyond oncology and dermatology.
“Speaking on the new ACI-Ethos clinical trial network, Kristen Khanna, PhD, MBA, stated that, “We look forward to continuing to expand ACI’s role in clinical trial conduct in specialty medicine by joining with Ethos investigators and their staff. Ethos already practices medicine at the highest level – this opportunity allows Ethos and ACI to share our science-driven mindset with study sponsors and pet owners.”
Kristen Khanna, PhD, MBA
ACI Chief Executive Officer
The opportunity for rapid and successful approval of innovative therapies is a key benefit to study sponsors, based on the following:
- Rapid accrual of data, resulting in faster studies, is enabled by the substantial caseload offered by the Ethos network and the optimized trial participation through ACI’s management
- Highly motivated and experienced clinicians and medical monitoring ensure quality data
- Ethos’ strategic focus on scientific innovation
Clinical studies in the areas of orthopedics, pain management, gastrointestinal disorders, immune mediated disease, oncology and the management of sepsis in dogs are currently being planned and will be among the first to be launched by the new ACI-Ethos multi-specialty network.